‘Dupilumab,’ moderate-to-severe eczema therapy, lands in Korea

‘Dupilumab,’ a moderate-to-severe eczema treatment for adults, will land in the Korean market.

As of 30 March, the Ministry of Food and Drug Safety(MFDS) approved Sanofi-Aventis Korea’s ‘Dupixent Prefilled Inj 300mg(generic name: dupilumab)’ as new drug.

‘Dupilumab’ is a targeted biologic therapy which inhibits the signals of interleukin-13(IL-13), one of the two major cytokines that is consi...